Member Info for KonarA

"Scancell believes this second mechanism of action has the potential to broaden the utilisation of the Moditope platform."

To what i wonder? When moditope was first announced they mentioned the potential for its use in other diseases. Could this relate to the Karolinska (arthritis) connection?

Yes i predicted a delay. I had my reasoning for predicting it. To be honest, when i made the prediction it was slightly tongue in cheek and in reference to the numerous delays before and the manner in which the board announced them.

But when you started with all the "This is nonsense. I know best. What i think is fact. This is just like Brexit and I know because whatever i think about Brexit is fact, and i can't seperate Brexit and Scancell. And also how dare you post opinion when I have opinions for you".. (or some other BS words to the same effect)

I just thought I'd make a mental note for the inevitable. And here we are... with you trying to wriggle out of it with arguments like "ah well a delay doesn't count if it wasn't the board that instigated the delay", as though any Board is going to unnecessarily delay their own trial.

No it was a prediction (not a predication).

It was based on the fact that the IND had not been submitted and it was unlikely that they would get it submitted, approved and recruiting before the year end.

I'm surprised now that you think it was only a 50 50.. given that at the time you argued so vehementlynthat it was nonsense.

Is it really that hard for you to admit you just got it wrong?

https://register.epo.org/documentView?number=US.201514614964.A&documentId=1-8-US++146149641EP1+

In case anyone missed this in the Spam

which is conveniently ignoring the actual prediction I made to start that thread, which was that the combi trial would be delayed to h1 2019.

isn't it funny just how many people "have to go out" as soon as they are asked to justify their postings.

"we still don't know the exact reason for the delay .. so how can you claim any friend knew in advance ?"

There is no friend. Its a meme, never mind.

"because they have not posted it on here before the RNS"

I did clearly post my prediction that the trial would be delayed, before the RNS. You tried to shoot holes in my prediction.

"Nobody expected this ... so lets not play games eh !"

...are you sure of that? Just asking for a friend.

Can't see how there cannot be an RNS tomorrow. In order to mention it at the AGM they will need to have RNS'd it first. And i am sure they will be desperate to deliver the info at the AGM.

it all gets a bit legal when you get down to the finer details, but Scancell currently have the one main application in the US. In Europe a couple of divisionals have been filed off the main approved patent and i wouldn't be surprised to see the same in the US. But fundamentally we now have the main patent in Europe, United States, Australia and South Africa.

Thanks. This is the big one i feel. Underpins the whole platform in the biggest market, and will be seen by the pharma's as a significant step.

thats the way i see it. Could be the last piece of the jigsaw.

Not the grapevine.. the info is out there in the public domain.

Try this link:

https://register.epo.org/documentView?number=US.201514614964.A&documentId=1-8-US++146149641EP1+

Much much better than that. I've just bought all i can afford anyway :-)

Due for tomorrows AGM. Well done to those who topped up at this level :-)

Would it help if you just gave us a list of approved topics?

Lets not forget:

"Sally Elizabeth Adams, 53, has worked as a consultant alongside Scancell since 2008 providing guidance through the drug development process. With 25 years’ industry experience, Sally has brought to Scancell her expertise in most aspects of drug discovery, including preparation and execution of clinical development plans from research to the clinic, scientific writing, implementation of quality control and documentation systems plus management of the SCIB1 clinical trial itself."

If i was very cynical i would say the timing of the RNS after most people have already voted for the AGM is a bit suss. I wonder what our major shareholders will make of this latest news.

i suspect you may be right.

It does seem to me that Moditope is (rightly) getting all the attention.

it was obvious with the amount of time left in the year, and no approval from the FDA to progress, that it was highly unlikely to start the trial this year. The BoD (not John Glencross) wrote in the Annual Results:

"Proposed international SCIB1 and checkpoint inhibitor combination trial planned to commence by end of 2018, subject to necessary regulatory approvals".

I agree that it is the FDA that is ultimately moving the trial, but i was told in non too polite terms that would not happen, and that I was fear mongering.

The reality is that the board have repeatedly stated that they are on track to start the trial, until the time comes and goes and the deadline is shifted. Lets not forget that this trial was originally forecast to have finished by now. I think we are long past due full disclosure of the status of this trial (or lack of) by the board. I am unable to attend the AGM due to work commitments, but if i was in attendance I would be pressing for a detailed explanation of how the board plan to take this, the SCIB2 and the MODI1 trial forward.

no it was Tf.. that was a direct cut and paste.